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OBJECTIVE—To examine whether sleep duration and quality are associated with fasting
glucose, fasting insulin, or estimated insulin resistance in a community-based sample of early
middle-aged adults.
RESEARCH DESIGN AND METHODS—This was an ancillary study to the Coronary
Artery Risk Development in Young Adults (CARDIA) Study. Habitual sleep duration and frag-
mentationwereestimatedfrom6daysofwristactigraphycollectedin2003–2005.Insomniawas
deﬁned as self-reporteddifﬁcultyfallingasleepor wakingup inthenightthreeor more timesper
week plus average sleep efﬁciency of ,80% based on actigraphy. Fasting blood samples to
measure glucose and insulin were collected after the sleep measures during the CARDIA clinical
examination in 2005–2006. Insulin resistance was estimated using the homeostatic model assess-
ment (HOMA) method. Analyses were cross-sectional and stratiﬁed by the presence of diabetes.
RESULTS—There was no association between sleep measures and fasting glucose, insulin, or
HOMA in the 115 subjects without diabetes. Among the 40 subjects with diabetes, after adjust-
ment for covariates, 10% higher sleep fragmentation was associated with a 9% higher fasting
glucose level, a 30% higher fasting insulin level, and a 43% higher HOMA level. Insomnia was
associatedwitha23%higherfastingglucoselevel,a48%higherfastinginsulinlevel,andan82%
higher HOMA level.
CONCLUSIONS—The observed association between poor sleep quality and higher glucose,
insulin, and estimated insulin resistance among subjects with diabetes warrants further exami-
nation of the effect of sleep disturbances on glucose control in type 2 diabetes.
Diabetes Care 34:1171–1176, 2011
T
he prevalence of type 2 diabetes
nearly doubled in the U.S. between
1980 and 2006, and rates have been
increasing rapidly throughout the world
(1). Diabetes can be a debilitating disease
associated with reduced quality-of-life,
severe complications, shorter life expec-
tancy, and increased economic burden
(2,3). Much effort has been devoted to
identifying factors associated with the in-
creased risk of developing type 2 diabetes
and improved prognosis of people with
type 2 diabetes to improve the lives of
millions of Americans. Disturbed sleep
has recently been proposed as a novel
risk factor.
Laboratory studies that manipulated
bedtimes observed impaired glucose
metabolism after sleep restriction com-
pared with sleep extension (4–6). These
laboratorystudieslastedonly1to2weeks
and the results may not reﬂect the effects
of habitual short sleep. Observational
studies have examined the association
between self-reported habitual sleep and
diabetes risk. Many have found cross-
sectional associations that indicated a
higher prevalence of diabetes among
short sleepers (7–9) and among those
with poor subjective sleep quality
(10,11). Several prospective studies
found higher rates of incident diabetes
associated with shorter sleep durations.
For example, a meta-analysis reported a
pooled risk ratio of 1.28 (95% CI 1.03–
1.60)associatedwithsleepduration#6h
compared with 7–8 h per night (12).
These observational studies all relied on
self-reported sleep, which may not be
very accurate (13). A small Italian study
did use wrist actigraphy to compare the
sleep of patientswith type2 diabetes with
healthycontrolsubjectsandfoundhigher
sleep fragmentation in the patients with
diabetes (14). Together, these studies
suggest that glucose metabolism may be
adversely affected by short sleep duration
and poor sleep quality.
The goal of the current study was to
examine whether sleep duration or qual-
ity measured using wrist actigraphy was
associated with levels of fasting glucose,
fasting insulin, or estimated insulin re-
sistance in a community-based sample of
early middle-aged adults.
RESEARCH DESIGN AND
METHODS—This study is ancillary
to a large, ongoing cohort study, the
Coronary Artery Risk Development in
Young Adults (CARDIA) Study, which
began in 1985–1986. CARDIA recruited
black and white adults aged 18–30 years
from four sites in the U.S., including Chi-
cago, which is the site involved in our
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ORIGINAL ARTICLEancillary study. Those who were not preg-
nant at the 2000–2001 CARDIA examina-
tion were eligible to participate in our
study, and 670 participants of 814
(82%) consented. Written informed con-
sent was obtained from each participant,
and this protocol was approved by the in-
stitutional review boards at Northwestern
University and the University of Chicago.
In 2003–2005, sleep measures were
collectedusingwristactigraphyandques-
tionnaires. In the 2005–2006 CARDIA
clinical examinationf a s t i n gb l o o ds a m -
ples were obtained along with other clin-
ical and demographic variables.
Glucose and insulin were both as-
sayed in the fasting blood sample. Each
participant was asked to fast for 12 h and
refrain from smoking for 2 h before the
examination. Participants were asked to
report the time of their last meal, and the
length of the fasting period was calcu-
lated. Glucose was measured on a Cobas
Mira Plus chemistry analyzer (Roche Di-
agnostic Systems, Indianapolis, IN) using
the hexokinase ultraviolet method. Insu-
lin was measured by radioimmunoassay
using an overnight equilibrium incuba-
tion format. As part of quality control, re-
assays of stored samples were conducted
and recalibration equations were devel-
oped for the glucose and insulin values
from the 2005–2006 CARDIA examina-
tion.Thecurrentreportusesthecalibrated
values of glucose and insulin.
Insulin resistance was estimated from
thehomeostaticmodelassessment(HOMA)
index, which was calculated as: [fasting
plasma insulin (mU/L) 3 fasting plasma
glucose(mmol/L)]/22.5(15).Highervalues
indicategreaterestimatedinsulinresistance.
A person was considered to have
diabetes if one of three criteria was met:
1) the participant had a fasting plasma
glucose level of $6.99 mmol/L, 2)h eo r
she reported having been diagnosed with
diabetes, or 3) he or she reported taking
medications identiﬁed as a treatment for
diabetes (e.g., insulin, Amaryl, Avandia,
Glucophage, glipizide, Glucotrol, metfor-
min).
Participants wore an Actiwatch-16
wrist activity monitor (Mini-Mitter Inc,
Bend, OR) for 3 days on two occasions
approximately 1 year apart between 2003
and 2005. These monitors use highly
sensitive omnidirectional accelerometers
to count the number of wrist movements
in 30-s epochs. The software scores each
30-s epoch as sleep or wake based on a
threshold of activity counts that is esti-
mated using activity within the epoch
being scored as well as the epochs 2 min
before and after that epoch. Bedtime and
wake time are set by the researcher using
the event markers, a sleep log, and data.
Wrist actigraphy has been validated
against polysomnography, demonstrating
a correlation for sleep duration between
0.82 in people with insomnia and 0.97 in
healthy subjects (16).
Sleep duration and fragmentation
were calculated using Actiware 3.4 soft-
ware, supplied by the manufacturer.
Sleep duration is the amount of actual
sleep obtained at night. Sleep fragmenta-
tion is an index of restlessness during the
sleep period expressed as a percentage. It
is calculated by summing two percent-
ages: 1) the percentage of the sleep
period spent moving (an epoch with .2
activity counts isconsidered moving) and
2) the percentage of the number of
immobile phases (consecutive epochs
with no movement) that are only #1
min long. For each participant, the
mean across all available nights was
used. For 92% of participants in these
analyses, 6 days of actigraphy recording
were available and the remaining 8% had
3 to 5 days of actigraphy recording.
We also created a dichotomous vari-
able to identify insomnia based on sub-
jectiveand objective assessmentsof sleep.
A person was considered to have insom-
nia if both of the following were true: 1)
on the Pittsburgh Sleep Quality Index
questionnaire (17), he or she reported not
falling asleep within 30 min three or more
timesperweekorwakingupinthemiddle
of the night three or more times per week,
2)his orheraveragesleep efﬁciency(sleep
duration divided by time in bed) from the
actigraphy data was ,80%.
ParticipantsalsocompletedtheBerlin
Sleep Apnea questionnaire (18). A partic-
ipant was considered to have frequent
snoring symptoms if he or she indicated
two of three of the following conditions
on this questionnaire: 1) snored three or
more times per week, 2) snoring was
louder than talking or very loud, or 3)
experienced breathing pauses three or
more times per week.
Covariates included race, sex, and
age. BMI (kg/m
2) was measured in
2005–2006. Finally, income (seven-level
ordinal variable ranging from ,$16,000
to $$100,000) and education (a ﬁve-
level ordinal variable: less than high
school, high school graduate, some col-
lege, college graduate, more than college
degree) in 2005–2006 were included in
the fully adjusted models.
Statistical analysis
Because the mechanisms of glucose regu-
lation are markedly different between
people with and without diabetes, all
analyseswerestratiﬁed bydiabetesstatus.
Means (SD) of all continuous variables
and proportions of categorical variables
were calculated. Differences in means
between those with and without diabetes
were tested using unpaired Student
t tests, and differences in proportions
were tested using x
2 tests. Linear regres-
sion models were used to examine the
cross-sectional association between the
sleep measures and fasting glucose, fasting
insulin, and HOMA of insulin resistance
(HOMA-IR) at the 20-year examination.
Each of the four sleep measures—sleep
duration, sleep fragmentation, insomnia,
and frequent snoring—was entered
into a separate regression model. Fasting
glucose, fasting insulin, and HOMA-IR
were all transformed using the natural
log in the analyses because they were
skewed to the right. The ﬁrst regression
model was unadjusted, and the second
model was adjusted for age, race, sex,
BMI,education,andincome.Therobust
variance estimator was used in linear re-
gression models to calculate conﬁdence
intervals and P values. All statistical
analyses were conducted using StataSE
10 software (StataCorp, College Station,
TX).
We excluded 9 participants with ,3
days of wrist actigraphy data, 87 who
reported a fasting period of ,8hb e f o r e
the clinical examination, 2 who were
missing a value for fasting glucose or fast-
ing insulin at 20 years, and one whose
diabetes status could not be ascertained,
w h i c hr e s u l t e di naﬁn a ls a m p l es i z eo f
571 participants.
RESULTS—Table 1 presents the means
(SD), and proportions of key variables in
the analysis stratiﬁed by diabetes status.
BMI, fasting glucose, fasting insulin,
HOMA-IR, and prevalence of insomnia
were all signiﬁcantly higher in the diabe-
tes group.
The results of the cross-sectional
analyses examining the association be-
tween the sleep measures and fasting
glucose, fasting insulin, and HOMA-IR
arepresentedin Table2.In subjectswith-
out diabetes in the unadjusted models,
frequent snoring was associated with
higher fasting glucose, higher insulin,
and higher HOMA values, and shorter
sleep duration was associated with higher
insulin levels and higher HOMA values,
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Sleep and markers of glucose metabolismbut these associations were no longer sta-
tistically signiﬁcant in the fully adjusted
models. Among subjects without diabe-
tes, the fully adjusted models showed in-
somnia was associated with lower insulin
levels and, as a direct result of lower in-
sulinlevels, lowerHOMA. Theregression
coefﬁcients indicated that having insom-
nia was associated with a 14% lower fast-
ing insulin level and a 14% lower HOMA
level.
Amongsubjectswithdiabetes,greater
sleep fragmentation and insomnia, but
not sleep duration, were associated with
higher fasting glucose, higher fasting in-
sulin, and higher HOMA even in the fully
adjusted models. Figure 1 presents the
unadjusted associations between sleep
fragmentation and each of the metabolic
variables. Figure 2 presents the associa-
tion between insomnia and each of the
metabolic variables. The regression coef-
ﬁcients from the fully adjusted regression
models (Table 2) indicated that among
subjectswithdiabetes,a10%highersleep
fragmentation was associated with a 9%
higher fasting glucose level, a 30% higher
fasting insulin level, and a 43% higher
HOMA value.
To translate these statistical associa-
tions, let us consider a diabetic patient
who has good sleep quality with sleep
fragmentation of only 5% and who has a
fastingglucoselevelof7.8mmol/L.Letus
consider a second diabetic patient with
identical demographics, but a sleep frag-
mentation of 15%, which is the clinical
thresholdforinsomnia.Hisorheraverage
fasting glucose level is estimated to be
0.7 mmol/L higher than the ﬁrst patient.
Finally, insomnia among subjects with
diabeteswasassociatedwitha23%higher
fasting glucose level, a 48% higher fasting
insulin level, and an 82% higher level of
HOMA. Again as an example, if two
patients differ only in the presence of
insomnia and the one without insomnia
had a fasting glucose level of 7.8 mmol/L,
the average fasting glucose level in the
patient with insomnia would be 1.6
mmol/L higher.
CONCLUSIONS—Our analyses sug-
gest that habitual sleep duration objec-
tively assessed by multiple days of wrist
actigraphy is not associated with markers
of glucose metabolism assessed after an
overnight fast in middle-aged adults with
and without diabetes. Sleep fragmenta-
tion and insomnia, however, were both
associated with higher fasting glucose,
insulin, and estimated insulin resistance,
but in subjects with diabetes only. Fre-
quent snoring, which is a possible in-
dicator of sleep-disordered breathing,
was associated with higher fasting glu-
cose, insulin, and insulin resistance in
subjects without diabetes in unadjusted
models only, which suggests that this
association may be mediated by one of
the covariates, such as BMI. Frequent
snoring was not signiﬁcantly associated
with any of the metabolic measures in
subjects with diabetes.
The lack of association between sleep
duration or fragmentation and fasting
glucose among subjects without diabetes
in our sample is consistent with labora-
tory studies of sleep restriction in both
young and middle-aged healthy subjects
(4–6,19). These studies observed a signif-
icant deleterious impact of experimentally
reduced sleep duration or quality on glu-
cose metabolism in response to a glucose
challenge,butdidnotobserveasigniﬁcant
change in fasting levels of glucose or in-
sulin.Twoepidemiologicstudiesinadults
also reported no association between
self-reported sleep duration and fasting
glucose, insulin, or HOMA in subjects
withoutdiabetes(9,20).Thus,theeffects
of short sleep duration or poor sleep
qualityonglucosemetabolisminhealthy
individualsmaybedetectableonlyaftera
glucose challenge.
It is possible that the effects of sleep
disturbances are more pronounced in
subjects with diabetes because the mech-
anisms responsible forglucosehomeosta-
sis are already deﬁcient and therefore
more vulnerable. Laboratory studies in
healthysubjectshaveindicatedthatlower
cerebralglucoseutilization,elevatedsym-
pathetic activity, higher evening cortisol
levels, alterations in growth hormone
release, and elevated markers of inﬂam-
mation are on the pathways that mediate
the adverse effects of reduced sleep dura-
tion or quality on glucose metabolism, or
both. Each of these pathways is already
dysregulated in the diabetic state and is
likely to be more vulnerable to an addi-
tional perturbation, such as sleep distur-
bance.
Our data suggest that the effect of
impaired sleep on glucose control in
patients with type 2 diabetes may be
clinically relevant. Among subjects with
diabetes, fragmented sleep and insomnia
wereassociatedwithfastingglucoselevels
that were 0.7–1.8 mmol/L higher than in
those who had well-consolidated sleep or
no insomnia. The strength of these asso-
ciations suggests that the diagnosis and
therapeutic treatment of type 2 diabetes
should take into account the possible ex-
istence of sleep disturbances.
Sleepdisturbancesmaybemorecom-
moninpeoplewithdiabetes(21).Astudy
in Italy found signiﬁcantly higher sleep
fragmentation using wrist actigraphy in
patients with type 2 diabetes compared
with healthy controls (14). We did not
observe signiﬁcant differences in sleep
fragmentation between subjects with
and without type 2 diabetes, but the
prevalence of insomnia symptoms in sub-
jectswithdiabeteswasdoublethatinthose
without diabetes. A variety of factors may
be responsible for the higher insomnia
prevalence among those with diabetes, in-
cluding increased pain associated with
Table 1—Description of sample by diabetes status
Variable
No diabetes (n = 531) Type 2 diabetes (n = 40) P
Mean (SD) Range Mean (SD) Range t test
Age (years) 45.2 (3.6) 37–52 45.6 (3.8) 38–51 0.51
BMI (kg/m
2)2 8 . 4 ( 6 . 5 ) 1 7 . 2 –61.0 37.9 (9.2) 24.3–60.3 ,0.0001
Glucose (mmol/L) 5.3 (0.5) 3.5–6.8 8.2 (2.7) 4.8–19.4 ,0.0001
Insulin (pmol/L) 79.1 (50.7) 4.5–504.8 151.2 (88.3) 46.2–493.1 ,0.0001
HOMA 3.1 (2.2) 0.2–21.9 9.1 (5.8) 2.1–30.2 ,0.0001
Actual sleep (hours) 6.1 (1.0) 2.6–8.8 5.9 (1.3) 2.3–7.7 0.18
Sleep fragmentation (%) 19.0 (7.8) 4.4–63.9 20.3 (8.7) 6.5–41.8 0.29
Sample (%) Sample (%) x
2 test
Women 57 70 0.11
African Americans 41 60 0.018
Insomnia 17 35 0.005
Frequent snorers 12 23 0.06
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Knutson and AssociatesTable 2—Cross-sectional analysis predicting the natural log of glucose, insulin, and HOMA from each sleep variable separately
stratiﬁed by diabetes*
Variable
Model 1 (unadjusted) Model 2 (adjusted)†
No diabetes Diabetes No diabetes Diabetes
Outcome: ln(glucose)
Sleep duration (h)
b –0.003 –0.022 0.006 0.033
95% CI –0.011 to 0.005 –0.084 to 0.040 –0.003 to 0.015 –0.032 to 0.097
P 0.46 0.48 0.20 0.31
Sleep fragmentation (per 10%)
b 0.008 0.133 0.001 0.089
95% CI –0.004 to 0.019 0.042–0.223 –0.010 to 0.012 0.006–0.172
P 0.199 0.005 0.89 0.036
Insomnia
b 0.001 0.285 –0.001 0.204
95% CI –0.022 to 0.024 0.069–0.501 –0.025 to 0.023 –0.006 to 0.414
P 0.94 0.011 0.93 0.056
Frequent snoring
b 0.031 –0.088 0.014 –0.148
95% CI 0.008–0.055 –0.290 to 0.113 –0.009 to 0.037 –0.323 to 0.026
P 0.008 0.38 0.23 0.092
Outcome: ln(insulin)
Sleep duration (h)
b –0.059 –0.042 0.011 –0.051
95% CI –0.111 to –0.007 –0.209 to 0.123 –0.038 to 0.060 –0.181 to 0.078
P 0.025 0.61 0.66 0.42
Sleep fragmentation (per 10%)
b 0.056 0.224 –0.015 0.264
95% CI –0.009 to 0.121 0.010–0.438 –0.073 to 0.042 0.086–0.441
P 0.093 0.040 0.60 0.005
Insomnia
b –0.059 0.216 -0.145 0.389
95% CI –0.203 to 0.085 –0.133 to 0.565 –0.275 to 20.014 –0.068 to 0.710
P 0.42 0.22 0.030 0.019
Frequent snoring
b 0.235 0.208 0.010 0.209
95% CI 0.073–0.397 –0.215 to 0.631 –0.133 to 0.153 –0.117 to 0.535
P 0.004 0.33 0.89 0.20
Outcome: ln(HOMA)
Sleep duration (h)
b –0.062 –0.065 0.017 –0.019
95% CI –0.118 to 20.007 –0.228 to 0.097 –0.036 to 0.070 –0.164 to 0.126
P 0.028 0.43 0.53 0.79
Sleep fragmentation (per 10%)
b 0.064 0.356 –0.015 0.353
95% CI –0.007 to 0.134 0.172–0.541 –0.075 to 0.046 0.197–0.508
P 0.077 ,0.001 0.64 ,0.001
Insomnia
b –0.058 0.501 –0.146 0.593
95% CI –0.212 to 0.096 0.123–0.880 –0.284 to 20.008 0.284 to 0.902
P 0.46 0.011 0.038 ,0.001
Frequent snoring
b 0.266 0.120 0.024 0.061
95% CI 0.09620.437 –0.378 to 0.618 –0.128 to 0.176 –0.307 to 0.428
P 0.002 0.63 0.76 0.74
Boldfacetypeindicates statisticalsigniﬁcance. *Eachsleep-relatedpredictor wasincludedin a separateregressionmodel.†Model 2is adjustedforage,race, sex, BMI,
education, and income.
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Sleep and markers of glucose metabolismneuropathy, nocturia, poor glucose con-
trol, and sleep-disordered breathing. Our
dataset does not provide indications on
the cause of insomnia in the participants
with type 2 diabetes.
Effects of insomnia on glucose me-
tabolism have not been studied exten-
sively. Insomnia often involves sleep loss
but can also include impaired sleep qual-
ity, including increased sleep fragmenta-
tion. Insomnia may be associated with
increased activity in the hypothalamic-
pituitary-adrenal axis (22), which could
impair glucose metabolism, particularly
in those whose metabolism is already
compromised.Thelinkbetweenthepres-
ence of insomnia and slightly, but signif-
icantly, lower fasting insulin values
without signiﬁcant elevation of glucose
levels in nondiabetic individuals with in-
somnia in our fully adjusted model is in-
triguing. An exploratory analysis showed
thatthisassociationbecamesigniﬁcantaf-
ter adjustment for BMI, and reﬂected the
contributionofthenondiabeticindividuals
with insomnia who were not overweight
(BMI ,25 kg/m
2). The unadjusted mean
(SD) fasting insulin level was 43.3 (20.7)
pmol/L in the 22 subjects with insomnia
and54.9(22.4)pmol/L inthe145 individ-
uals without insomnia. This ﬁnding will
need replication in a larger sample.
This study has some limitations that
need to be considered. First, our study
design does not allow for determination
of causal direction. Although available
evidencefromepidemiologicandlaboratory
studiessupportstheconceptthatdisturbed
sleep impairs glucose metabolism, poorly
controlled glucose levels may also impair
sleep (21).
Second, we do not have polysomno-
graphic measures of sleep in this cohort,
so we cannot accurately detect sleep
disorders like obstructive sleep apnea,
which appears to be highly prevalent in
patients with type 2 diabetes (23) and is
associated with poorer glycemic control
(24). We did use a validated screening
questionnaire and examined the frequent
snoring component of this questionnaire
as a surrogate marker of apnea risk, but
frequent snoring was not associated with
any of the outcome measures in the fully
adjusted models.
A third limitation is that participants
reported having fasted for at least 8 h, but
there was no way to objectively verify
whether they were indeed fasting. Thus,
some of the glucose and insulin measures
may not have been representative of a
fasting state. Another important limitation
is that the sample only contained 40
individuals with diabetes, which is consis-
tent with the mean age of the participants.
Finally, sleep was not assessed imme-
diately before the clinical examination,
but previous analysis of the actigraphy
data demonstrated little year-to-year var-
iability (25). Future research should en-
roll larger numbers of diabetic patients
and measure glucose metabolism in a
controlled setting.
Patients with type 2 diabetes are at a
higher risk of diabetes complications if
their glucose levels are poorly controlled.
Our analyses indicated an association
between poor sleep quality and higher
glucose, insulin, and estimated insulin
resistance that is likely to be of clinical
signiﬁcance. Additional research to ex-
amine the effect of impaired sleep on
glycemic control in people with type 2
diabetes is important. If improving sleep
can help improve glucose control in
people with diabetes, then a potentially
new therapeutic intervention may be
identiﬁed.
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